ClinicalTrials.gg
CompletedNCT02227173DDIUpdated Nov 18, 2014

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

A Phase 1 interventional study of BMS-986020 and Montelukast in Drug-drug Interaction Study, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-11-18.

Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is an open-label, single-sequence, drug-drug interaction study in healthy male and female subjects. There is no formal research hypothesis to be statistically tested. It is expected that coadministration of BMS-986020 with montelukast, flurbiprofen, and digoxin may increase the exposure of montelukast, flurbiprofen, and digoxin.

02

Conditions studied

  • Drug-drug Interaction Study
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female nonsmoking subjects ages 18 to 50 years, inclusive, with a of 18.0 to 32.0 kg/m2, inclusive
  • Women of must agree to follow instructions for methods of for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • History of arrhythmias or palpitations associated with dizziness or fainting
  • History of cardiac disease

Other protocol defined exclusion criteria could apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Single-Sequence, A B C

    Treatment A: Single oral dose of montelukast, flurbiprofen, and digoxin on Day 1 Treatment B: BMS-986020 orally twice daily (BID) on Day 8 through Day 10 Treatment C: BMS-986020 orally BID, single oral dose of montelukast, flurbiprofen, and digoxin on Day 11; BMS-986020 BID on Day 12 through Day 17

    Drug: BMS-986020 · Drug: Montelukast · Drug: Flurbiprofen · Drug: Digoxin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters (maximum observed plasma concentration, area under the concentration-time curve) for montelukast, flurbiprofen, and digoxin

    Pharmacokinetic endpoints for montelukast, flurbiprofen, and digoxin with and without BMS-986020

    Time frame: Predose and up to 168 hours post dose

Secondary outcomes

  1. Additional pharmacokinetic parameters for montelukast, flurbiprofen, and digoxin.

    Additional pharmacokinetic parameters for montelukast, flurbiprofen, digoxin, and with and without BMS-986020

    Time frame: Predose and up to 168 hour post dose

  2. Safety

    Collection of adverse events and other physical parameters to assess safety

    Time frame: From dosing (Day 1) to Day 21

07

Study locations

1 site
  • Healthcare Discoveries, LLC d/b/a ICON Development Solutions
    San Antonio, Texas 78209, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2014
First posted
Aug 27, 2014
Start
Sep 2014
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Last update
Nov 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02227173
Responsible party
Sponsor
First posted
Aug 27, 2014
Start date
Sep 2014
Primary completion
Nov 2014
Completion
Nov 2014
Last update
Nov 18, 2014

Study contacts

Emanuel DeNoia, MD
principal investigator · ICON Development Solutions
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BMS-986020 · Montelukast · Flurbiprofen

Start the discussion